Abstract
Objective: Since 2002-2007, we applied boron neutron capture therapy (BNCT) to >50 cases of malignant gliomas (MGs) with epithermal neutron irradiations. Recently, we showed the early radiographical improvement of malignant glioma patients by our modified BNCT, with simultaneous use of BPA (borono-phenylalanine) and BSH (sodium borocaptate). In this time, we focused on the survival benefit from BNCT for the newly diagnosed glioblastoma patients. Methods: BNCT group including 21 newly histological confirmed glioblastoma patients treated with surgical removal followed by BNCT in Osaka Medical College during 2002-2006 period. Ten patients were treated with BNCT only, and in the other 11 patients, 20-30 Gy fractionated external beam X-ray irradiation therapy (XRT) was performed after BNCT. No chemotherapy was administered until tumor progression was observed. Results: Treatments were well tolerated. Any kind of acute systemic or local severe toxicity were not demonstrated. Mean over all survival of the patients treated by BNCT was 20.7 and the median was 15.6 months with 2-years survival of 25%. Stratification by RPA criteria showed 6, 6, 8 and 1 patients, respectively, in classes III-VI. Three patients out of six in class III and one out of eight in class V are alive at the end point of this study. All the patients in classes IV and VI died. Median survival time for the BNCT group compared to the RTOG database was as follows: 20.6 months vs. 17.9 months for class III; 16.9 months vs. 11.1 months for class IV; 13.2 months vs. 8.9 months for class V. Conclusion: The RTOG RPA prognostic criteria were helpful in establishing which class of glioma patients could potentially benefit from BNCT. BNCT showed a survival benefit in all of the RPA classes of the RTOG database not only for the good prognosis group.
| Original language | English |
|---|---|
| Journal | Applied Radiation and Isotopes |
| Volume | 67 |
| Issue number | 7-8 SUPPL. |
| DOIs | |
| Publication status | Published - Jul 2009 |
Fingerprint
Keywords
- Boron neutron capture therapy
- BPA
- BSH
- External beam X-ray irradiation
- Glioblastoma
ASJC Scopus subject areas
- Radiation
Cite this
Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. / Kawabata, Shinji; Miyatake, Shin Ichi; Nonoguchi, Naosuke; Hiramatsu, Ry; Iida, Kyoko; Miyata, Shiro; Yokoyama, Kunio; Doi, Atsushi; Kuroda, Yuzo; Kuroiwa, Toshihiko; Michiue, Hiroyuki; Kumada, Hiroaki; Kirihata, Mitsunori; Imahori, Yoshio; Maruhashi, Akira; Sakurai, Yoshinori; Suzuki, Minoru; Masunaga, Shin Ichiro; Ono, Koji.
In: Applied Radiation and Isotopes, Vol. 67, No. 7-8 SUPPL., 07.2009.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients
AU - Kawabata, Shinji
AU - Miyatake, Shin Ichi
AU - Nonoguchi, Naosuke
AU - Hiramatsu, Ry
AU - Iida, Kyoko
AU - Miyata, Shiro
AU - Yokoyama, Kunio
AU - Doi, Atsushi
AU - Kuroda, Yuzo
AU - Kuroiwa, Toshihiko
AU - Michiue, Hiroyuki
AU - Kumada, Hiroaki
AU - Kirihata, Mitsunori
AU - Imahori, Yoshio
AU - Maruhashi, Akira
AU - Sakurai, Yoshinori
AU - Suzuki, Minoru
AU - Masunaga, Shin Ichiro
AU - Ono, Koji
PY - 2009/7
Y1 - 2009/7
N2 - Objective: Since 2002-2007, we applied boron neutron capture therapy (BNCT) to >50 cases of malignant gliomas (MGs) with epithermal neutron irradiations. Recently, we showed the early radiographical improvement of malignant glioma patients by our modified BNCT, with simultaneous use of BPA (borono-phenylalanine) and BSH (sodium borocaptate). In this time, we focused on the survival benefit from BNCT for the newly diagnosed glioblastoma patients. Methods: BNCT group including 21 newly histological confirmed glioblastoma patients treated with surgical removal followed by BNCT in Osaka Medical College during 2002-2006 period. Ten patients were treated with BNCT only, and in the other 11 patients, 20-30 Gy fractionated external beam X-ray irradiation therapy (XRT) was performed after BNCT. No chemotherapy was administered until tumor progression was observed. Results: Treatments were well tolerated. Any kind of acute systemic or local severe toxicity were not demonstrated. Mean over all survival of the patients treated by BNCT was 20.7 and the median was 15.6 months with 2-years survival of 25%. Stratification by RPA criteria showed 6, 6, 8 and 1 patients, respectively, in classes III-VI. Three patients out of six in class III and one out of eight in class V are alive at the end point of this study. All the patients in classes IV and VI died. Median survival time for the BNCT group compared to the RTOG database was as follows: 20.6 months vs. 17.9 months for class III; 16.9 months vs. 11.1 months for class IV; 13.2 months vs. 8.9 months for class V. Conclusion: The RTOG RPA prognostic criteria were helpful in establishing which class of glioma patients could potentially benefit from BNCT. BNCT showed a survival benefit in all of the RPA classes of the RTOG database not only for the good prognosis group.
AB - Objective: Since 2002-2007, we applied boron neutron capture therapy (BNCT) to >50 cases of malignant gliomas (MGs) with epithermal neutron irradiations. Recently, we showed the early radiographical improvement of malignant glioma patients by our modified BNCT, with simultaneous use of BPA (borono-phenylalanine) and BSH (sodium borocaptate). In this time, we focused on the survival benefit from BNCT for the newly diagnosed glioblastoma patients. Methods: BNCT group including 21 newly histological confirmed glioblastoma patients treated with surgical removal followed by BNCT in Osaka Medical College during 2002-2006 period. Ten patients were treated with BNCT only, and in the other 11 patients, 20-30 Gy fractionated external beam X-ray irradiation therapy (XRT) was performed after BNCT. No chemotherapy was administered until tumor progression was observed. Results: Treatments were well tolerated. Any kind of acute systemic or local severe toxicity were not demonstrated. Mean over all survival of the patients treated by BNCT was 20.7 and the median was 15.6 months with 2-years survival of 25%. Stratification by RPA criteria showed 6, 6, 8 and 1 patients, respectively, in classes III-VI. Three patients out of six in class III and one out of eight in class V are alive at the end point of this study. All the patients in classes IV and VI died. Median survival time for the BNCT group compared to the RTOG database was as follows: 20.6 months vs. 17.9 months for class III; 16.9 months vs. 11.1 months for class IV; 13.2 months vs. 8.9 months for class V. Conclusion: The RTOG RPA prognostic criteria were helpful in establishing which class of glioma patients could potentially benefit from BNCT. BNCT showed a survival benefit in all of the RPA classes of the RTOG database not only for the good prognosis group.
KW - Boron neutron capture therapy
KW - BPA
KW - BSH
KW - External beam X-ray irradiation
KW - Glioblastoma
UR - http://www.scopus.com/inward/record.url?scp=67649390794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649390794&partnerID=8YFLogxK
U2 - 10.1016/j.apradiso.2009.03.015
DO - 10.1016/j.apradiso.2009.03.015
M3 - Article
VL - 67
JO - Applied Radiation and Isotopes
JF - Applied Radiation and Isotopes
SN - 0969-8043
IS - 7-8 SUPPL.
ER -